Stefan Fröhling

Professor Stefan Fröhling serves as Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg and heads the Division of Translational Medical Oncology at the German Cancer Research Center (DKFZ). His research focuses on precision oncology, molecular characterization of tumors, and clinical trials for targeted therapies.

• 2020: Managing Director, NCT Heidelberg
• 2019: Head of Division, Translational Medical Oncology, DKFZ
• 2012–present: Attending Physician, NCT Heidelberg/DKFZ and Heidelberg University Hospital

Fröhling’s research emphasizes precision oncology through molecular profiling and functional characterization of tumors. Key areas include:

• Development of tools for tumor molecular analysis
• Clinical trials on molecularly targeted therapies
• Investigation of bone/soft-tissue sarcomas and leukemias
• Integration of genomic/transcriptomic data in treatment strategies

His recent publications highlight work on:

• Targeting oncogenic dependencies in leukemia (e.g., RET-mediated autophagy)
• Molecular characterization of sarcomas (e.g., leiomyosarcoma genomics)
• Exploiting genetic alterations (KIT, FGFR1, BRAF) for therapeutic interventions

Fröhling has received prestigious awards including:

• Uncommon Collaboration Award (2018)
• Young Investigator Fellowship (2009–2011)
• Research Fellowship from German Research Foundation (2005–2007)
• Leukemia Research Award (2004)

As a clinician-scientist, Fröhling bridges translational research with clinical practice, contributing to advancing therapies for hematologic malignancies and sarcomas through interdisciplinary collaboration.